Evaluation Of Plasma LncRNA-MALAT1 And LncRNA-ATB Expression In The Diagnosis Of Non-small Cell Lung Cancer

ObjectiveThe purpose of this study is to evaluate the clinical value of plasma lncRNA-MALAT1 and lncRNA-ATB as biomarkers in the diagnosis of non-small cell lung cancer(NSCLC).MethodIn this study,quantitative real-time PCR(qRT-PCR)technique was carried out to determine the expression levels of plasma lncRNA-MALAT1 and lncRNA-ATB in 60 patients with NSCLC and 60 patients with benign lung disease(BLD).The potential correlations between plasma lncRNA-MALAT1 and lncRNA-ATB levels and clinical pathological characteristics in NSCLC patients were analyzed.Receiver operating characteristic(ROC)curves was plotted by statistical software,and area under the ROC curve(AUC)was used to assess the performance of plasma lncRNA-MALAT1 and lncRNA-ATB in the diagnosis of NSCLC.The cut-off values were defined based on ROC curves to calculate sensitivity,specificity,positive predictive value(PPV),negative predictive value(NPV)and accuracy.Meanwhile,the data obtained above were compared with data obtained from detection of serum carcinoembryonic antigen(CEA)and cytokeratin-19-fragment(Cyfra21-1)for diagnosing NSCLC.Result1.The plasma levels of lncRNA-MALAT1(P<0.05)was markedly reduced and lncRNA-ATB(P<0.05)was significantly elevated in NSCLC patients as compared with BLD patients.2.The plasma levels of lncRNA-MALAT1 and lncRNA-ATB in NSCLC patients were not correlated with gender,age,smoking index,histopathological type and tumor TNM stage(P>0.05).3.The ROC curves illustrated relatively distinct difference between the NSCLC patients and BLD patients,with an AUC of 0.777(95% CI,0.692~0.861)for lncRNA-MALAT1 and0.784(95% CI,0.701~0.867)for lncRNA-ATB,which was slightly higher than the AUCs of CEA(0.744,95% CI,0.657~0.831)and Cyfra21-1(0.714,95% CI,0.623~0.805).4.The combination of lncRNA-MALAT1 and lncRNA-ATB yielded a higher AUC(0.853,95% CI,0.784~0.923)compared to lncRNA-MALAT1 or lncRNA-ATB alone when diagnosing NSCLC.Moreover,the AUCs obtained by combining the two plasma lncRNAs with serum CEA or Cyfra21-1 was 0.904(95% CI,0.85~0.959)and 0.892(95% CI,0.836~0.948).ConclusionPlasma lncRNA-MALAT1 and lncRNA-ATB could be used as biomarkers in the diagnosis of NSCLC,and the combination of lncRNA-MALAT1 and lncRNA-ATB had a higher diagnostic performance compare to lncRNA-MALAT1 or lncRNA-ATB alone.Last,combining the two plasma lncRNAs with CEA or Cyfra21-1 which is classical tumor biomarker could further enhance the diagnostic efficacy for NSCLC.